First clinical experiences with the tetravalent live vaccine against dengue (Qdenga ®) in travellers: a multicentric TravelMedVac study in Germany.
A study was conducted to assess the safety and tolerability of the tetravalent live-attenuated dengue vaccine Qdenga®, which received marketing approval in Germany in 2022. The study evaluated vaccine-related reactions in a...
Read More